Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.73 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | AOC2 | O75106 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2149447 | 0.98 | TAAR1 (0.70) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL3706426 | 0.93 | TAAR1 (0.70) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL21726316 | 0.91 | TAAR1 (0.67) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL29263666 | 0.91 | TAAR1 (0.67) | TAAR1MAOBLOXL2MAOAAOC3 | |
| Hydrochloric Acid SCHEMBL7393435 | 0.91 | TAAR1 (0.67) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL1567051 | 0.91 | TAAR1 (0.67) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL7005631 | 0.91 | TAAR1 (0.67) | TAAR1MAOBLOXL2MAOAAOC3 | |
| SCHEMBL1091307 | 0.88 | TAAR1 (0.57) | TAAR1MAOBLOXL2 | |
| Oxalic Acid SCHEMBL31633764 | 0.88 | TAAR1 (0.57) | TAAR1MAOBLOXL2MAOAHTR2A | |
| SCHEMBL3678682 | 0.87 | MAOA (0.62) | TAAR1LOXL2MAOAHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552838-A | Amine dehydrogenase catalytic system, application thereof and eutectic solvent and preparation thereof | 河北工业大学 | 2025-03-04 | — | — | CN | claimed |
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2022-06-23 | — | — | US | claimed |
| CN-113512029-A | Preparation and application of substituted pyrazole compound containing pyrimidinamine | 沈阳中化农药化工研发有限公司 | 2021-10-19 | — | — | CN | claimed |
| WO-2020130592-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | 서울대학교산학협력단 | 2020-06-25 | — | — | WO | claimed |
| EP-1651605-B1 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-05-02 | — | — | EP | claimed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | claimed |
| EP-1648874-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-10-05 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-7763618-B2 | 1-Pentyl-3-{6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]-pyridin-3-yl}urea; inhibitors of stearoyl-CoA desaturase; cardiovascular disease, diabetes, obesity, metabolic syndrome | XENON PHARMACEUTICALS INC. (CA) | 2010-07-27 | — | — | US | claimed |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | ALI MOHAMMED A | 2010-03-04 | — | — | US | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| US-20040082601-A1 | Anti-inflammatory compounds | SCOTT MALCOLM K (US) | 2004-04-29 | — | — | US | claimed |
| US-20030171585-A1 | Triphenylpropanamide compounds | SCOTT MALCOLM K (US) | 2003-09-11 | — | — | US | claimed |
| EP-0966430-A1 | ANTI-INFLAMMATORY COMPOUNDS | Ortho-Mcneil Pharmaceutical Corp. (US) | 1999-12-29 | — | — | EP | claimed |
| WO-1999033786-A1 | ANTI-INFLAMMATORY COMPOUNDS | ORTHO-MCNEIL PHARMACEUTICAL CORPORATION (US) | 1999-07-08 | — | — | WO | claimed |
| EP-0443573-A2 | HIV protease inhibitors containing derived amino acids | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
| EP-0443560-A2 | HIV protease inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) | 1991-08-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194969-A1 | METAL HALIDE PEROVSKITE LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING SAME | HCN4, SLC46A1, FES | TAAR1 4232/4885MAOB 880/4885LOXL2 3274/4885 |
| US-20040082601-A1 | Anti-inflammatory compounds | TNF, PTGES, PTGES2 | TAAR1 3941/4885MAOB 2123/4885LOXL2 812/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | TAAR1 2591/4885MAOB 1042/4885LOXL2 1533/4885 |
| US-20030171585-A1 | Triphenylpropanamide compounds | PTGES, PTGES2, MPO | TAAR1 3293/4885MAOB 1445/4885LOXL2 2683/4885 |
| US-20100056460-A1 | COMBINATION OF ORGANIC COMPOUNDS | REN, IAPP, ACE | TAAR1 2579/4885MAOB 1331/4885LOXL2 4285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.